Objective:

To introduce Avarept, the first marketed dry eye therapy in the TRPV1 antagonist class, in Japan.

Key Findings:

• Avarept is the first dry eye therapy targeting TRPV1 antagonism.
• Dry eye disease affects over 20 million people in Japan, with increasing prevalence due to aging and lifestyle factors.
• Current treatments often provide incomplete relief, highlighting the need for new therapeutic options.

Interpretation:

Avarept's introduction marks a significant advancement in dry eye disease management, offering a new mechanism of action that may improve patient outcomes.

Limitations:

• The long-term safety and efficacy of Avarept remain to be fully established.
• The study results are based on a specific population in Japan, which may limit generalizability.

Conclusion:

Avarept represents a promising new option for patients suffering from dry eye disease, addressing a critical need for effective therapies.